KROS
NASDAQ · Biotechnology

Keros Therapeutics Inc

$10.85
+0.02 (+0.18%)
As of Nov 7, 2:01 AM ET ·
Financial Highlights (FY 2026)
Revenue
114.86M
Net Income
40.95M
Gross Margin
—
Profit Margin
35.7%
Rev Growth
—
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin — — 50.8% 50.8%
Operating Margin 27.7% -5,345.1% -16.0% -16.9%
Profit Margin 35.7% -5,013.7% -15.0% -17.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 114.86M 4.38M 103.26M 79.84M
Gross Profit — — 52.49M 40.58M
Operating Income 31.80M -233,970,055 -16,499,040 -13,532,511
Net Income 40.95M -207,966,613 -15,524,708 -13,846,639
Gross Margin — — 50.8% 50.8%
Operating Margin 27.7% -5,345.1% -16.0% -16.9%
Profit Margin 35.7% -5,013.7% -15.0% -17.3%
Rev Growth — -43.9% +11.8% -2.5%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 173.40M 194.80M
Total Equity — — 374.54M 364.51M
D/E Ratio — — 0.46 0.53
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 32.51M -245,260,567 -22,220,211 -17,087,554
Free Cash Flow — — -17,331,210 -15,756,938